Pharmacokinetic and pharmacodynamic properties of meropenem

被引:184
作者
Nicolau, David P. [1 ]
机构
[1] Hartford Hosp, Ctr Anti Infect Res & Dev, Hartford, CT 06102 USA
关键词
D O I
10.1086/590064
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Pharmacokinetic and pharmacodynamic profiles of antibiotics are important in determining effective dosing regimens. Although minimum inhibitory concentration (MIC) data reflect microbial susceptibility to an antibiotic, they do not provide dosing information. The integration of pharmacokinetic and microbiological data, however, can be used to design rational dosing strategies. Meropenem is a broad-spectrum beta-lactam antibiotic that penetrates most body fluids and tissues rapidly after intravenous administration. Meropenem undergoes primarily renal elimination; therefore, dosage adjustment is required for patients with renal impairment. Meropenem is indicated for the treatment of complicated skin and skin-structure infections, complicated intra-abdominal infections, and bacterial meningitis. Meropenem has time-dependent bactericidal activity; thus, the percentage of time that free-drug concentrations are higher than the MIC (%T > MIC) characterizes the drug's pharmacodynamic profile (bactericidal target of similar to 40%T > MIC). Pharmacodynamic modeling can identify regimens with the greatest probability of attaining this target, and probabilities can be compared with clinical and microbiological responses in patients.
引用
收藏
页码:S32 / S40
页数:9
相关论文
共 57 条
[11]   Bactericidal activities of meropenem and ertapenem against extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model [J].
DeRyke, C. Andrew ;
Banevicius, Mary Anne ;
Fan, Hong Wei ;
Nicolau, David P. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (04) :1481-1486
[12]  
DeRyke CA, 2006, DRUGS, V66, P1, DOI 10.2165/00003495-200666010-00001
[13]   Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug' [J].
Drusano, GL .
NATURE REVIEWS MICROBIOLOGY, 2004, 2 (04) :289-300
[14]   Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients [J].
Du, XL ;
Li, CH ;
Kuti, JL ;
Nightingale, CH ;
Nicolau, DP .
JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (01) :69-75
[15]   Pharmacodynamic evaluation of meropenem and cefotaxime for pediatric meningitis: A report from the OPTAMA program [J].
Ellis J.M. ;
Kuti J.L. ;
Nicolau D.P. .
Pediatric Drugs, 2006, 8 (2) :131-138
[16]   PHARMACODYNAMICS OF INTRAVENOUS CIPROFLOXACIN IN SERIOUSLY ILL-PATIENTS [J].
FORREST, A ;
NIX, DE ;
BALLOW, CH ;
GOSS, TF ;
BIRMINGHAM, MC ;
SCHENTAG, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1073-1081
[17]   Once-daily dosing of aminoglycosides: review and recommendations for clinical practice [J].
Freeman, CD ;
Nicolau, DP ;
Belliveau, PP ;
Nightingale, CH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (06) :677-686
[18]   Tissue penetration of meropenem in patients undergoing gynecologic surgery [J].
Gall, S ;
Hemsell, DL ;
McGregor, JA ;
Martens, MG ;
Pitkin, D ;
Allen, S .
CLINICAL INFECTIOUS DISEASES, 1997, 24 :S178-S180
[19]   SIMULATION OF HUMAN PLASMA-LEVELS OF BETA-LACTAMS IN MICE BY MULTIPLE DOSING AND THE RELATIONSHIP BETWEEN THE THERAPEUTIC EFFICACY AND PHARMACODYNAMIC PARAMETERS [J].
HATANO, K ;
WAKAI, Y ;
WATANABE, Y ;
MINE, Y .
CHEMOTHERAPY, 1994, 40 (01) :1-7
[20]   A COMPILATION OF MEROPENEM TISSUE DISTRIBUTION DATA [J].
HUTCHISON, M ;
FAULKNER, KL ;
TURNER, PJ ;
HAWORTH, SJ ;
SHEIKH, W ;
NADLER, H ;
PITKIN, DH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 36 :43-56